Kiniksa Pharmaceuticals International plc-A 2024年度报告

Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filingrequirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 ofRegulationS-T during the preceding 12months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” inRule12b-2 of the Exchange Act. Large Accelerated Filer☐Accelerated Filer☒Non-accelerated Filer☐SmallerReportingCompany☐Emerging Growth Company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in thefiling reflect the correction of an error to previously issued financial statements.☐Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒As of the last business day of the Registrant’s most recently completed second fiscal quarter, June 28, 2024, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the ordinary shares on The Nasdaq Global Select Market wasapproximately $697.4million. As of February 21, 2025, there were72,644,240ordinary shares outstanding in aggregate, comprised of:42,009,500Class A ordinary shares, nominal value $0.000273235 per share1,795,158Class B ordinary shares, nominal value $0.000273235 per share12,781,964Class A1 ordinary shares, nominal value $0.000273235 per share16,057,618Class B1 ordinary shares, nominal value $0.000273235 per share DOCUMENTS INCORPORATED BY REFERENCEPortions of the registrant’s definitive proxy statement for its 2025 Annual Meeting of Shareholders, which the registrant intends to file with the Securities and Exchange Commissionpursuant to Regulation14A within 120 days after the end of the registrant’s fiscal year ended December31, 2024, are incorporated byreference into PartIII of this Annual Report on Form 10-K. Kiniksa Pharmaceuticals International,plc FORM10-K FOR THE YEAR ENDED DECEMBER 31, 2024 TABLE OF CONTENTS PART I Item 1. BusinessItem 1A. Risk FactorsItem 1B. Unresolved Staff CommentsItem 1C. CybersecurityItem 2. PropertiesItem 3. Legal ProceedingsItem 4. Mine Safety Disclosures 7399999100100100 PART II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and IssuerPurchases of Equity Securities101Item 6. Reserved.102Item 7. Management’s Discussion and Analysis of Financial Condition and Results ofOperations103Item 7A. Quantitative and Qualitative Disclosures About Market Risk116Item 8. Financial Statements and Supplementary Data116Item 9. Changes in and Disagreements with Accountants on Accounting and FinancialDisclosure117Item 9A. Controls and Procedures117Item 9B. Other Information118Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.118PART IIIItem 10. Directors, Executive Officers and Corporate Governance119Item 11. Executive Compensation119Item 12. Security Ownership of Certain Beneficial Owners and Management and RelatedStockholder Matters119Item 13. Certain Relationships and Related Transactions, and Director Independence119Item 14. Principal Accounting Fees and Services119PART IVItem 15. Exhibits and Financial Statement Schedules120Item 16. Form 10-K Summary125 SPECIAL NOTEREGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (this “Annual Report”) contains forward-lookingstatements. All statements other than statements of historical facts contained in this Annual Reportincluding statements regarding our commercial strategy; potential value drivers; potential indications;potential market opportunities and competitive position; ongoing, planned and potential clinical trialsand other studies; timing and potential impact of clinical data; future results of operations andfinancial posi